Biomarker development has historically been driven by the discovery of genes involved in the regulation of key carcinogenic processes in specific tumor types (such as estrogen receptor in breast cancer, BRC-ABL in chronic myeloid leukemia, etc.)and has been tightly linked to cancer drug development. The gene discussed is ESR1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.